Other treatment

ApprovedSmall molecule

Other treatment is one of 55 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Multiple SclerosisActive, not recruiting

Chronic Obstructive Pulmonary DiseaseApproved

Active, not recruiting

Multiple SclerosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Other treatment

Novartis

Approved

1 2

Kesimpta

Novartis

Preclinical

15 3

Avonex

EMD Serono

Preclinical

22 4

Campath

GGenzyme, a Sanofi Company

Preclinical

12 5

Zinbryta

Roche

Preclinical

2 6

Pred Forte

Myfortic

Novantrone

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

3 10

Lunesta

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Not yet recruiting

Multiple Sclerosis

NCT07149662

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator

Completed· Novartis logo

Novartis·Phase 4·NCT01794780·2,229 enrolled

Multiple Sclerosis1 trial

Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy

Not yet recruiting·RRegion Stockholm··NCT07149662·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Other treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Other treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Other treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Other treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News